Picture of Cypherpunk Technologies logo

CYPH — Cypherpunk Technologies News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Cypherpunk Technologies swings to Q2 profit on Zcash gains

Cypherpunk Technologies swings to Q2 profit on Zcash gains


Overview

  • US privacy tech firm's Q2 net income turned positive, driven by unrealized gains on Zcash holdings

  • Q2 diluted EPS was $0.18, reversing a loss in the prior yr

  • Research and development expenses fell sharply after clinical trial completion and workforce reduction


Outlook

  • Company has initiated a strategic process to advance the sirexatamab program, including possible partnerships or spin-out

  • No assurance that the strategic process will result in any transaction or financing

  • Cypherpunk continues to focus on Zcash accumulation and sees growing demand for digital privacy


Result Drivers

  • ZCASH PRICE GAINS - Q2 net income benefited from a $46 mln unrealized gain on ZEC holdings as the price rose from $243.35 to $400.09

  • LOWER R&D SPENDING - Research and development expenses fell after clinical trial completion and workforce reduction

  • HIGHER ADMIN COSTS - General and administrative expenses rose due to increased stock-based compensation and payroll


Company press release: ID:nPreryDdla


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

$0.18

Q2 Net Income

$39.40 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Cypherpunk Technologies Inc is $0.90, about 32.4% above its August 11 closing price of $0.68


Reuters Recommended Reads

  • Aug 11 - Fold Q2 revenue falls, misses estimates as bitcoin prices pressure activity

  • Aug 10 - Bakkt Q2 revenue falls 70% on digital asset trading slowdown

  • Aug 11 - Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Cypherpunk Technologies

See all news